news
9 January 2017 | By Niamh Marriott (Drug Target Review)
The monoclonal antibody biopharmaceutical group Kymab announced today that it has received a $9m grant from the Bill & Melinda Gates Foundation to accelerate the development of novel vaccines and therapeutics for infectious diseases, including HIV.